BridgeMD
New treatment option for Heterozygous Familial Hypercholesterolemia
Official title A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
ClinicalTrials.gov ID: NCT06164730
What this study is testing
What is VERVE-102?
VERVE-102 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for heterozygous familial hypercholesterolemia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Diagnosis of HeFH or premature CAD
You likely can't join if
- Homozygous familial hypercholesterolemia
- Active or history of chronic liver disease
- Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol
The study team makes the final eligibility decision.
Where it's taking place
- Dothan, Alabama, United States
- Pomona, California, United States
- Boca Raton, Florida, United States
- Jacksonville, Florida, United States
- Winter Park, Florida, United States
- High Point, North Carolina, United States
- DeSoto, Texas, United States
- Renton, Washington, United States
- Adelaide, Australia
- Melbourne, Australia
- Sydney, Australia
- Chicoutimi, Canada
- Hamilton, Canada
- Montreal, Canada
- Québec, Canada
- Toronto, Canada
- Vancouver, Canada
- Rehovot, Israel
- Christchurch, New Zealand
- Birmingham, United Kingdom
+ 4 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dothan, Alabama, United States; Pomona, California, United States; Boca Raton, Florida, United States; Jacksonville, Florida, United States; Winter Park, Florida, United States; High Point, North Carolina, United States and 18 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.